Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

 

Commercial North America Immune Disorders

Bayer Aims To Take AI-Driven One Drop Beyond Diabetes

Bayer is boosting its AI drive by investing in One Drop’s digital platform and hopes to advance outcomes in oncology, heart disease and women’s health with data-driven solutions.

 

Digital Health Companies Financing

Autolus Faces Life After Woodford With New Czech Backer

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

United Kingdom Financing Companies

Spotlight On APAC

Digital Health Trends: Asia Catching Up But Hurdles Remain

Digital health initiatives are rapidly emerging in Asia amid robust innovation and rising R&D activities in the region, but there are still some hurdles to overcome. An executive from Pfizer talks to Scrip about some of the major trends, opportunities and challenges.

Asia Pacific South Korea

Advertisement


 Recent Tweets from Scrip


Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Prescription Influencer Shifts In India: Is Pharma Geared Up?

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

Commercial Strategy

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Sanofi To Co-Develop Digital Therapeutic For MS Patients

Sanofi's latest digital health move will see it collaborating with Happify Health on a digital therapeutic for patients with multiple sclerosis, a therapeutic area it knows well.

 

Digital Health Deals

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?

Leadership Strategy

Versantis Gets Cash For Toxin 'Undelivery' Product

Emerging Company Profile: CHF16m for Swiss firm that engineers liposomes to capture toxins and protect the organs of patients with acute liver failure.

 

StartUps and SMEs Companies

Cynata In Potential Japan Double As Fujifilm Acquires Lead Asset

Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.

Deals Regenerative Medicine
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

US FDA AdComm Win For Aimmune’s Palforzia Bodes Well For DBV’s Peanut Allergy Patch

Aimmune’s oral immunotherapy seems destined to come to market with a strict REMS, though analysts do not expect this will impact adoption. DBV is awaiting word on whether the FDA will review its second attempt at a BLA submission for Viaskin Peanut.

Advisory Committees Drug Review

Novartis Takes Piqray To India With Affordability Pledge

Novartis’s breast cancer therapy Piqray is endorsed by an expert panel for marketing in India and the Swiss company has emphasized its commitment to value-based pricing for the product.

Policy & Regulation India

Will Purdue Bankruptcy Filing Resolve 'Unrelenting Chaos' Of Opioid Litigation?

Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.

Legal Issues Policy
See All

Research & Development Explore this Topic

Set Alert for Research & Development

IPF Failure Sets Back Biogen’s Diversification Efforts

The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.

Clinical Trials Business Strategies

Purdue's Opioid Rescue Drug Development To Continue Under A New Company

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Companies Research & Development

Acceleron Ends ACE-083 FSHD Testing After Phase II Failure

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.

Neurology Clinical Trials
See All
UsernamePublicRestriction

Register

Advertisement